Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "REGOMA-OS Study Analyzing Regorafenib Efficacy & Safety in Recurrent Glioblastoma Patients"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Giuseppe Lombardi
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Giuseppe Lombardi
Comments 0
Login to view comments.
Click here to Login
